We found a match
Your institution may have rights to this item. Sign in to continue.
- Title
抗真菌感染新药研究进展.
- Authors
张玉; 陈思敏; 郭诗雨; 侯炜彤; 姜远英; 安毛毛
- Abstract
The morbidity and mortality of invasive fungal infections (IFIs) are on the increase in recentyears owing to the growing number of immunodeficient patients, and lead to a serious threat to human health. At present, triazoles (fluconazole), polyenes (amphotericin B) and echinocandins (caspofungin), as routine anti-IFIs drugs, are widely administrated in clinical practice. However, the present therapeutic regime in IFIs remains dismal despite decades of efforts in anti-IFIs drugs. Therefore, evaluating the correlation between frontier antifungal drugs and their effects on clinical phases were warranted. In this review, we present various therapeutic targets, including fungal cell wall, cell membrane, cell metabolism, and biological agents. CD101 and SCY-078 inhibiting glucan synthase, nikkomycins Z inhibiting chitin synthase, APX001 inhibiting GPI-anchored protein, VT-1161 and VT-1129 inhibiting fungal CYP51, CAmB disrupting cell membrane permeability, F901318 inhibiting pyrimidine synthesis, cell surface lectin-like sequence 3 protein vaccine (NDV-3) and antifungal infection antibody mycograb were also fully discussed. Besides, this article reviews the research progress of the anti-IFIs drugs as mentioned above, including the functional mechanism, activities in vitro and vivo, outcomes of clinical research, providing an overview of diverse anti-IFIs in the past decades and an outlook for the development of related drugs.
- Subjects
GLUCAN synthase; PHARMACOLOGY; CHITIN synthase; FUNGAL cell walls; MEMBRANE permeability (Biology); CELL permeability; BACTERIAL cell walls
- Publication
Mycosystema, 2019, Vol 38, Issue 8, p1253
- ISSN
1672-6472
- Publication type
Article
- DOI
10.13346/j.mycosystema.190065